1. Home
  2. PCRX vs SGP Comparison

PCRX vs SGP Comparison

Compare PCRX & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$22.83

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$27.10

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCRX
SGP
Founded
2006
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
932.9M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
SGP
Price
$22.83
$27.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$35.33
$45.00
AVG Volume (30 Days)
736.7K
87.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
107.44
N/A
EPS
0.16
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$9.77
N/A
Revenue Next Year
$9.71
N/A
P/E Ratio
$140.38
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$24.71
52 Week High
$27.99
$30.56

Technical Indicators

Market Signals
Indicator
PCRX
SGP
Relative Strength Index (RSI) 52.95 56.74
Support Level $20.41 $25.38
Resistance Level $23.82 $30.02
Average True Range (ATR) 1.01 1.63
MACD 0.02 -0.19
Stochastic Oscillator 68.81 45.81

Price Performance

Historical Comparison
PCRX
SGP

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: